Evidence map›Paper›PMID 29636122›Full record

ReviewBMB reports2018

The role of necroptosis in the treatment of diseases.

Young Sik Cho

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in BMB reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03758118 (Neuroprotection and Neuroenhancement in a Model of Optic Nerve Neurodegeneration), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03758118 nacompletednot on this map

Neuroprotection and Neuroenhancement in a Model of Optic Nerve Neurodegeneration (Non Arteritic Ischemic Optic Neuropathy): Study of Morpho-functional Changes Related to Treatment With Citicoline Oral Solution

TypeinterventionalSponsorFondazione G.B. Bietti, IRCCSRan2017 to 2018Enrolled40ConditionsNon-arteritic Ischemic Optic NeuropathyArmsCiticoline
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Diversity and complexity of cell death: a historical review.Experimental & molecular medicine · 2023
    Review
  15. Review
  16. Anastasis: cell recovery mechanisms and potential role in cancer.Cell communication and signaling : CCS · 2022
    Review
  17. Article
  18. Crosstalk between cGAS-STING signaling and cell death.Cell death and differentiation · 2020
    Review
  19. Mechanisms and pathogenesis underlying environmental chemical-induced necroptosis.Environmental science and pollution research international · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Young Sik ChoDepartment of Pharmacy, Keimyung University, Daegu 42601, Korea.
Keimyung University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necroptosis is an emerging form of programmed cell death occurring via active and well-regulated necrosis, distinct from apoptosis morphologically, and biochemically. Necroptosis is mainly unmasked when apoptosis is compromised in response to tumor necrosis factor alpha. Unlike apoptotic cells, which are cleared by macrophages or neighboring cells, necrotic cells release danger signals, triggering inflammation, and exacerbating tissue damage. Evidence increasingly suggests that programmed necrosis is not only associated with pathophysiology of disease, but also induces innate immune response to viral infection. Therefore, necroptotic cell death plays both physiological and pathological roles. Physiologically, necroptosis induce an innate immune response as well as premature assembly of viral particles in cells infected with virus that abrogates host apoptotic machinery. On the other hand, necroptosis per se is detrimental, causing various diseases such as sepsis, neurodegenerative diseases and ischemic reperfusion injury. This review discusses the signaling pathways leading to necroptosis, associated necroptotic proteins with target-specific inhibitors and diseases involved. Several studies currently focus on protective approaches to inhibiting necroptotic cell death. In cancer biology, however, anticancer drug resistance severely hampers the efficacy of chemotherapy based on apoptosis. Pharmacological switch of cell death finds therapeutic application in drug- resistant cancers. Therefore, the possible clinical role of necroptosis in cancer control will be discussed in brief. [BMB Reports 2018; 51(5): 219-224].

Indexed as

ApoptosisDiseaseAnimalsHumansModels, BiologicalNecrosisSignal Transduction

Identifiers

PMID29636122
PMCPMC5988575
OpenAlexW2807151245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.